It is almost 20 years since the concept of patientcontrolled analgesia was popularized. Unlike many apparently good ideas that, for a variety of reasons, never come to fruition, both the concept and application of this approach to drug delivery were rapidly embraced by the medical and lay community. Gambling and colleagues in Vancouver adapted equipment designed for intravenous drug administration and trialed this new approach among women requesting epidural analgesia in labour, with immediate success 1 . For obstetric analgesia, patientcontrolled inhalational analgesia (with nitrous oxide) had survived the test of time, following its introduction in the 1880s and the development of the Minnitt apparatus in the 1930s. Its availability remains widespread in many countries. It was hardly surprising that patient-controlled epidural delivery techniques were also met with enthusiasm, not just by a few obstetric anaesthetists, but more importantly by the consumer-women focusing on both new technologies and greater personal involvement in their experience of childbirth. Early investigations suggested that parturients were likely to consider patient-controlled epidural analgesia (PCEA) a highly satisfactory method of pain relief 2 , and in Western Australia, a parliamentary report recommended that the option of self-administration should be made more widely available 3 . Nevertheless, in developed countries, few practitioners and units were sufficiently enthusiastic and motivated to introduce this approach to their labour and delivery epidural service. Ten years after the first description of PCEA during labour, only a third of large Australasian maternity units offered PCEA as an alternative to intermittent anaesthetistor midwife-administered boluses, or continuous infusion techniques 4 .
In contrast to patient-controlled intravenous analgesia, which dramatically and rapidly changed postoperative pain management, largely supplanting both intramuscular and nurse-controlled infusion techniques, labour PCEA was not clearly more reliable or effective. Despite theoretical advantages with respect to safety, there was insufficient evidence to support the postulate that it might reduce complication rates or improve obstetric outcome. Information about some of these aspects of care remains very limited. Nevertheless, evidence has continued to emerge supporting advantages over alternative approaches, both when PCEA is applied routinely and for specific parturients. Compared with both intermittent bolus and continuous infusion epidural analgesia, PCEA reduces staff workload as a result of fewer additional supplements; and compared with continuous infusion methods it reduces drug consumption, supplementary doses, and delays the development of unwanted motor block 5, 6 .
In this issue of the journal, Missant and colleagues 7 report the results of a trial designed to address one of the persisting conundrums about PCEA during labour: is it worthwhile using a continuous background infusion, in addition to patient boluses, supplied on demand? The investigators found that the addition of a very low rate of infusion (2 ml/h) resulted in a statistically (and clinically) significant reduction in episodes of breakthrough pain requiring intervention, compared with demand-only boluses of ropivacaine 0.15% plus sufentanil (4 ml at a 15 minute lockout interval). The merit of a continuous infusion in this setting has been debated since 1992, when the first study to investigate this method reported no benefit 8 . Within a short time, another clinical trial, using different PCEA variables, found that an infusion reduced interventions and improved pain relief 9 . There had been only limited further investigation until 2004 10 . Using 0.1% ropivacaine with sufentanil (bolus 5 ml with 5 min lockout interval), and a continuous infusion at 0, 3, 6 or 9 ml/h, no difference in quality of analgesia, number of supplementary boluses or satisfaction was found. An increasing infusion rate increased drug consumption with no adverse effect on labour outcome. Although this study may have been underpowered, I was prompted to comment that the case for addition of a continuous infusion remained unproven 11 . In the last six months however, we are fortunate that several new trials have shed more light on this matter, with further research in progress 12 . A large Canadian multicentre study of 300 nulliparous women evaluated boluses of 0.08% ropivacaine with fentanyl (5 ml with a 10 minute lockout interval), with or without a 10 ml/h infusion. Parturients receiving the 10 ml/h background infusion experienced less pain, received fewer unscheduled boluses and reported higher satisfaction scores 13 . Importantly, although those parturients randomized to the continuous background infusion received more drug, there was no difference in obstetric outcome 14 . In a recent German study, more episodes of moderate or high pain score were seen with demand-only PCEA 15 .
How do we reconcile the apparent outcome differences in these trials? First, the study populations are not always comparable, the inclusion criteria varying with regard to parity, the stage of labour at study entry, and the inclusion or exclusion of women not proceeding to vaginal delivery. Second, the methods of assessment and the threshold at which intervention occurred varied. For example, not all studies evaluated fluctuations in pain intensity and the reason for intervention with a supplementary epidural dose of local anaesthetic, if not criterionbased, is likely to differ among different units and populations. Third, the relationship between concentration of local anaesthetic, demand dose, duration of lockout interval and characteristics of the supplementary dose is complex. With intrapartum PCEA, it would be simplistic to think that "one shoe fits all": it is hardly surprising that study results are not uniform. Nevertheless, evidence is now accumulating that under certain conditions, a background continuous infusion may either limit periods of increased pain intensity, or reduce extra doses, without increasing motor block.
It is, nevertheless, clear that PCEA, by demand only, can provide high quality labour and delivery analgesia, with potential advantages over continuous infusion or intermittent bolus approaches. If PCEA is made available, the decision as to which solutions and variables are employed may well be influenced by local considerations, including regulatory issues, costs and the philosophy of the unit and its customers. The nature of the epidural service and who provides it is relevant, given that a background infusion will reduce the number of additional supplements. The implications for human resource demand where anaesthetists, rather than midwives, are required to provide such extra boluses, are considerable. In addition to electronic ambulatory pumps, disposable patientcontrolled analgesia devices, which do not allow a background infusion, are available. In my own institution, where a comprehensive anaesthetic-and midwifery-managed epidural service is provided, we have not felt compelled to change current practice, given a long history of safe and effective use of demand-only PCEA using disposable devices.
Patient-controlled epidural analgesia for labour and delivery has not taken the obstetric world by storm, and the introduction of spinal-epidural analgesia has further increased the options, but placing the parturient's finger on the button is not a passing fad. From personal observation, the implementation of PCEA services, in Australia at least, is continuing. PCEA does not appeal to every parturient by any means, but it is an effective and safe method of epidural drug administration, associated with high levels of maternal satisfaction 16 . The detail of whether epidural drugs are best delivered by the patient alone, or as supplements to a predetermined (and subtherapeutic) rate of continuous infusion, is interesting. To my mind, however, the question, "Should a background infusion be included during PCEA for labour and delivery (and at what rate)?" is of far less importance than "Why shouldn't some method of PCEA be offered to this woman?' 
EDITORIALS
Anaesthesia and Intensive Care, Vol. 33, No. 4, August 2005 What is the role of processed EEG monitoring in anaesthesia? Do I use the BIS on my next patient? This question is being debated by industry, regulatory authorities, the public, societies of anaesthetists and perhaps, soon, the lawyers.
The B-Aware trial is by far the most important trial relevant to this debate 1 . The B-Aware trial provided good evidence that BIS can reduce awareness in a population at high risk of awareness. It also collected a wealth of useful information about the nature of awareness, and provided data on important secondary endpoints. In this issue Professor Leslie and others present data gathered during the B-Aware trial which analyses the effect of BIS-guided anaesthesia on recovery times 2 .
In this trial the use of BIS was associated with shorter recovery-a matter of a few minutes after long procedures. Importantly, times were measured to discharge eligibility not actual discharge. The B-Aware trial data provides only a weak argument for using BIS to quicken recovery times. The importance of Professor Leslie's paper is that the reduction in awareness was not bought at the potential expense of delayed recovery due to deeper anaesthesia. Other studies have also shown minimal or modest improvements in recovery times after the use of BIS 3 . Many see the primary role of BIS as awareness prevention. Apart from the B-Aware trial, only one other study has investigated BIS in this role. This Swedish study demonstrated a low rate of awareness when using the BIS in routine paralysed cases 4 . Lack of any contemporary control arm for comparison limits the level of evidence of this study. How relevant are these studies to your next patient? Is the data relevant when we use other EEG technologies or BIS with a different version of the algorithm? Clinical trials are vexed by the question: how much should I apply the results from a study to my individual patient, who is not the average study population patient? It can be argued that trends of benefit found in high risk groups are likely to be repeated in subgroups or related groups-although to differing degrees 5 . It can also be argued that failure to adhere to trial conditions can qualitatively alter outcomes from benefit to risk. In one recent audit of awareness, BIS was associated with a non-significant increase in awareness 6 . It is most likely this was due to confounding variables; alternatively these findings may suggest that use of BIS is only of benefit when adhering to strict protocol as in the B-Aware trial.
From the time of Galen, predicting outcome in the art of medicine has relied on a balance of previous To BIS or not to BIS?
